Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   40628   clinical trials with a EudraCT protocol, of which   6628   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-001995-12
    Sponsor's Protocol Code Number:I10E-0901
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-07-12
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-001995-12
    A.3Full title of the trial
    A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in patients with Multifocal Motor Neuropathy
    Estudio europeo aleatorizado, doble ciego, controlado con tratamiento comparador activo y de diseño cruzado que evalúa la seguridad y eficacia de una nueva formulación líquida y lista para usar de inmunoglobulina intravenosa humana al 10 % (I10E) en comparación con Kiovig® en pacientes con neuropatía motora multifocal
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in patients with Multifocal Motor Neuropathy
    Estudio europeo aleatorizado, doble ciego, controlado con tratamiento comparador activo y de diseño cruzado que evalúa la seguridad y eficacia de una nueva formulación líquida y lista para usar de inmunoglobulina intravenosa humana al 10 % (I10E) en comparación con Kiovig® en pacientes con neuropatía motora multifocal
    A.4.1Sponsor's protocol code numberI10E-0901
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLFB BIOTECHNOLOGIES
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportLFB BIOTECHNOLOGIES
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationLFB BIOTECHNOLOGIES
    B.5.2Functional name of contact pointClinical trial information desk
    B.5.3 Address:
    B.5.3.1Street AddressZA de Courtaboeuf, 3, avenue des Tropiques
    B.5.3.2Town/ cityLes Ulis Cedex
    B.5.3.3Post code91940
    B.5.3.4CountryFrance
    B.5.4Telephone number+33169 82 70 10
    B.5.5Fax number+33169 82 72 72
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name KIOVIG
    D.2.1.1.2Name of the Marketing Authorisation holderBaxter AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameKIOVIG
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN NORMAL IMMUNOGLOBULIN
    D.3.9.3Other descriptive nameHUMAN NORMAL IMMUNOGLOBULIN (IV)
    D.3.9.4EV Substance CodeSUB12041MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namehuman normal immunoglobulin for intravenous administration
    D.3.2Product code I10E
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN NORMAL IMMUNOGLOBULIN
    D.3.9.2Current sponsor codeI10E
    D.3.9.3Other descriptive nameHUMAN NORMAL IMMUNOGLOBULIN (IV)
    D.3.9.4EV Substance CodeSUB12041MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Multifocal motor neuropathy (MMN)
    Neuropatía motora multifocal (NMM)
    E.1.1.1Medical condition in easily understood language
    Multifocal motor neuropathy (MMN) is a chronic acquired, probably autoimmune, demyelinating, motor neuropathy. It is a rare disease. The mean age at onset is 40 years (range 20-70 years).
    Es una enfermedad crónica adquirida, probablemente autoinmune, desmielinizante, neuropatía motora. Se trata de una enfermedad rara. La edad media de inicio es de 40 años (rango 20-70 años).
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level PT
    E.1.2Classification code 10065579
    E.1.2Term Multifocal motor neuropathy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate the efficacy of I10E compared to Kiovig® for maintenance treatment of patients with MMN in a randomised, double-blind, active comparator-controlled, cross-over design.
    El primer objetivo del estudio es evaluar la eficacia y la seguridad de I10E en comparación con Kiovig® para el tratamiento de mantenimiento de la NMM en un estudio aleatorizado, doble ciego, de diseño cruzado con tratamiento comparador activo.
    E.2.2Secondary objectives of the trial
    The secondary objective of this study is to assess the safety.
    El objetivo secundario del estudio es evaluar la seguridad.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    A patient may be included in the study if all of the following criteria are fulfilled:

    1. Male or female patient aged 18 to 80 years.

    2. Written informed consent obtained prior to any study-related procedures.

    3. Diagnosis of definite or probable MMN according to the EFNS/PNS Guideline 2010, First revision made by neuromuscular disease specialists with specific electrodiagnostic expertise.

    4. Patients treated with a stable maintenance dose (without any change in doses > or < 15% ) of any brand of IVIG (Kiovig excluded) at 1 g/kg body weight every 4-week intervals up to 2 g/kg body weight every 4-week to 8-week intervals according to the EFNS/PNS Guideline 2010, First revision for at least 3 months prior to enrolment.

    5. Covered by national health care insurance system if required by local regulations.
    Se podrá incluir a un paciente en el estudio si se cumplen todos los criterios siguientes:
    1.Varones o mujeres de entre 18 y 80 años.
    2. Obtención del consentimiento informado por escrito antes de que se realice cualquier procedimiento relacionado con el estudio.
    3. Diagnóstico de NMM demostrada o probable según las directrices del EFNS/PNS de 2010, Primera revisión realizada por especialistas en enfermedades neuromusculares con experiencia específica en electrodiagnóstico.
    4. Pacientes tratados con una dosis de mantenimiento estable (sin ninguna modificación de la dosis > o < 15 %) de cualquier tipo de IGIV (excepto Kiovig®) de entre 1 g/kg de peso corporal en intervalos de 4 semanas y 2 g/kg de peso corporal en intervalos de 4 a 8 semanas, según las directrices del EFNS/PNS de 2010, primera revisión, durante al menos los 3 meses previos a la inclusión.
    5. Pacientes con cobertura en el sistema nacional de salud, si lo requiere la normativa local.
    E.4Principal exclusion criteria
    A patient may be included in the study if none of the following criteria is met:

    1. Upper motor neuron, bulbar, cranial nerve or significant sensory deficit.

    2. CSF protein >100 mg/dL (if available and done as part of a previous evaluation).

    3. Any disease that may cause neuropathy or may interfere with outcome assessments, such as diabetes, vasculitis, or systemic lupus erythematosus.

    4. BMI ? 40 kg/m2.

    5. Known hypersensitivity to the active substance or to any of the excipients of I10E (glycine and polysorbate 80) or Kiovig® (glycine).

    6. History of Kiovig® use.

    7. History of IgA deficiency, except if the absence of anti-IgA antibodies is documented.

    8. Patient infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

    9. Protein-losing enteropathy characterised by serum protein levels <60 g/l and serum albumin levels <30 g/l or nephrotic syndrome characterised by proteinuria ?3.5 g /24 hours, serum protein levels <60 g/l and serum albumin levels <30 g/l.

    10. History of cardiac insufficiency (New York Heart Association (NYHA) III/IV) or uncontrolled severe hypertension.

    11. History of thrombotic episodes (including deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident).

    12. Glomerular filtration rate <80 ml/min/1.73m2 measured according to the Modified Diet in Renal Disease (MDRD) calculation.

    13. Serum levels of AST, ALT and/or ALP >2 times upper limit of normal range.

    14. Patient treated with immunomodulator/immunosuppressor (e.g. cyclophosphamide, cyclosporine or interferon), except use at the same dose of: methotrexate, mycophenolate mofetil, or azathioprine for at least 6 months before the inclusion visit.

    15. Treatment with an anti-CD20 antibody within the 12 previous months.

    16. Administration of another investigational product within the last month prior to inclusion.

    17. Exposure to blood products or derivatives other than commercial IgG, within 3 months prior to inclusion.

    18. Positive results of pregnancy blood test or breast-feeding woman, or woman of childbearing potential without effective contraception for the duration of the study.

    19. Any serious medical condition that would interfere with the clinical assessment of I10E or prevent the patient from complying with the protocol requirements.

    20. Anticipated poor compliance of patient with study procedures during the 12 month duration of the study.

    21. Drug or alcohol abuse.
    Se podrá incluir a un paciente en el estudio si no cumple ninguno de los siguientes criterios:
    1.Déficit de la neurona motora superior, bulbar, del nervio craneal o déficit sensorial significativo.
    2.Proteínas en el LCR > 100 mg/dl (si se dispone de esta información, obtenida como parte de una evaluación previa).
    3.Cualquier enfermedad que pueda provocar neuropatía o pueda interferir con el resultado de las evaluaciones, tales como diabetes, vasculitis o lupus eritematoso sistémico.
    4.IMC ? 40 kg/m2.
    5.Hipersensibilidad conocida al principio activo o a alguno de los excipientes de I10E (glicina y polisorbato 80) o Kiovig® (glicina).
    6.Antecedentes de tratamiento con Kiovig®.
    7.Antecedentes de deficiencia de IgA, excepto si se ha documentado ausencia de anticuerpos anti-IgA.
    8.Paciente con infección por el virus de la hepatitis B (VHB) y/o hepatitis C (VHC), o virus de la inmunodeficiencia humana (VIH).
    9.Enteropatía perdedora de proteínas caracterizada por niveles de proteína sérica < 60 g/l y niveles de albúmina sérica < 30 g/l o síndrome nefrótico caracterizado por proteinuria igual o mayor a 3,5 h/24 horas, niveles de proteína sérica < 60 g/l y niveles de albúmina sérica < 30 g/l.
    10.Antecedentes de insuficiencia cardíaca (Grado III/IV de la New York Heart Association (NYHA)) o hipertensión grave no controlada.
    11.Antecedentes de episodios trombóticos (incluidos trombosis venosa profunda, embolia pulmonar, infarto de miocardio y accidente cerebrovascular).
    12.Tasa de filtración glomerular < 80 ml/min/1,73m2 determinada con el cálculo de la dieta modificada en la enfermedad renal (MDRD).
    13.Niveles de AST, ALT y/o FA > 2 veces el límite superior de normalidad.
    14.Pacientes tratados con inmunomoduladores/inmunosupresores (p. ej., ciclofosfamida, ciclosporina o interferón), excepto si se han usado a la misma dosis que metotrexato, micofenolato mofetilo o azatioprina durante al menos los 6 meses anteriores a la visita de inclusión.
    15.Tratamiento con un anticuerpo anti-CD20 en los 12 meses previos.
    16.Administración de otro producto en investigación en el mes previo a la inclusión.
    17.Exposición en los 3 meses previos a la inclusión a otros productos sanguíneos o hemoderivados diferentes de la IgG comercializada.
    18.Resultados positivos en una prueba de embarazo en sangre o mujeres en periodo de lactancia o en edad fértil que no utilicen un método anticonceptivo eficaz durante todo el estudio.
    19.Cualquier enfermedad grave que pudiera interferir en la evaluación clínica de I10E o impedir que el paciente cumpla los requisitos del protocolo.
    20.Previsión de incumplimiento del paciente de los procedimientos del estudio durante los 12 meses del estudio.
    21.Alcoholismo o toxicomanía.
    E.5 End points
    E.5.1Primary end point(s)
    Difference between I10E and Kiovig® in the original MMRC 10 sum score (10 muscles on both sides see Table 20.1) described by Cats 2008
    Diferencia entre I10E y Kiovig® en la puntuación total de la escala modificada 10 del MRC (10 músculos en ambos lados, véase la Tabla 20.1) descrita por Cats 2008
    E.5.1.1Timepoint(s) of evaluation of this end point
    - Before the course

    - Efficacy assessments between 13 and 25 weeks for each period and depending on courses frequencies

    - End of study visit
    - Antes del curso

    - Las evaluaciones de eficacia entre semanas 13 y 25 para cada periodo y dependiendo de las frecuencias de los cursos

    - Fin de la visita de estudio
    E.5.2Secondary end point(s)
    Difference between I10E and Kiovig® in:
    ? MMRC 10 new sum score (10 slightly different muscles on both sides chosen because they are expected to be more relevant and responsive to change; see Table 20.1)
    ? Rasch built MMRC sum score (based on the 10 muscles in the MMRC sum score described by Cats 2008)
    ? MMRC 14 sum score (14 muscles on both sides)
    ? Grip strength with dynamometer in the most affected hand
    ? Need for change of the IVIG dose or frequency due to a worsening of the patient?s neurological status with IMPs.
    ? Change of Clinical Global Impression (CGI)
    ? Discontinuation of study treatment
    ? INCAT: upper and lower limbs
    Diferencia entre I10E y Kiovig® en:
    ?Nueva puntuación total en la escala modificada 10 del MRC (elección de 10 músculos ligeramente diferentes en ambos lados porque se espera que sean más importantes y respondedores al cambio; véase la Tabla 20.1)

    ?Puntuación total en la escala modificada del MRC mediante el análisis de Rasch (basada en los 10 músculos de la puntuación total de la escala modificada del MRC, descrita por Cats 2008)

    ?Puntuación total en la escala modificada 14 del MRC (14 músculos en ambos lados)

    ?Fuerza de presión determinada con un dinamómetro en la mano más afectada
    ?Necesidad de modificación de la dosis o de la frecuencia de administración de la IGIV debido a un empeoramiento del estado neurológico del paciente con los PEI.
    ?Cambio en la Impresión Clínica Global (CGI)
    ?Suspensión del tratamiento del estudio
    ?INCAT: extremidades superiores e inferiores
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Before the course

    - End of study visit

    - For INCAT: assessments between 13 and 25 weeks for each period and depending on courses frequencies

    - For Grip strength: 2 weeks (15-18 days) after the last course of each period
    - Antes del curso

    - Fin de la visita de estudio

    - Para INCAT: evaluaciones entre la semana 13 y 25 para cada periodo y dependiendo de la frecuencia de los cursos

    - Para la fuerza de presión: 2 semanas (15-18 días) después del último curso de cada período
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Active comparator
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA18
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 16
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 4
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 20
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the last visit patients will be switched to the normal standard of care for the condition.
    Al finalizar el estudio, los pacientes serán tratados según la práctica clínica habitual.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-07-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-05-15
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2016-07-01
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA